title: Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia.
abstract: Serotonin-1A (5-HT(1A)) receptors may play a role in schizophrenia and the effects of certain antipsychotic drugs. However, the mechanism of interaction of 5-HT(1A) receptors with brain systems involved in schizophrenia, remains unclear. Here we show that 5-HT(1A) receptor knockout mice display enhanced locomotor hyperactivity to acute treatment with amphetamine, a widely used animal model of hyperdopaminergic mechanisms in psychosis. In contrast, the effect of MK-801 on locomotor activity, modeling NMDA receptor hypoactivity, was unchanged in the knockouts. The effect of the hallucinogen 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) was markedly reduced in 5-HT(1A) receptor knockout mice. There were no changes in apomorphine-induced disruption of PPI, a model of sensory gating deficits seen in schizophrenia. Similarly, there were no major changes in density of dopamine transporters (DAT) or dopamine D(1) or D(2) receptors which could explain the behavioural changes observed in 5-HT(1A) receptor knockout mice. These results extend our insight into the possible role of these receptors in aspects of schizophrenia. As also suggested by previous studies using agonist and antagonist drugs, 5-HT(1A) receptors may play an important role in hallucinations and to modulate dopaminergic activity in the brain.
authors.affiliation: Behavioural Neuroscience Laboratory, Mental Health Research Institute, Parkville, Melbourne, Australia. m.vandenbuuse@mhri.edu.au
authors.forename: Maarten
authors.initials: M
authors.lastname: van den Buuse
authors.forename: Emma
authors.initials: E
authors.lastname: Ruimschotel
authors.forename: Sally
authors.initials: S
authors.lastname: Martin
authors.forename: Victoria B
authors.initials: VB
authors.lastname: Risbrough
authors.forename: Adam L
authors.initials: AL
authors.lastname: Halberstadt
mesh_terms: D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D005260:Female; D006213:Hallucinogens / Q000494:pharmacology*; D008297:Male; D008732:Methoxydimethyltryptamines / Q000494:pharmacology*; D051379:Mice; D057507:Mice, 129 Strain; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D011897:Random Allocation; D044282:Receptor, Serotonin, 5-HT1A / Q000172:deficiency* / Q000235:genetics; D012559:Schizophrenia / Q000378:metabolism*
chemical_list: D006213:Hallucinogens; D008732:Methoxydimethyltryptamines; D044282:Receptor, Serotonin, 5-HT1A; D000661:Amphetamine